Bristol-Myers Squibb Co (NYSE:BMY) has been assigned a consensus recommendation of “Hold” from the twenty-four research firms that are currently covering the stock. One analyst has rated the stock with a sell recommendation, eleven have given a hold recommendation and eleven have given a buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $61.81.

Several equities analysts have weighed in on the stock. Jefferies Group LLC restated a “buy” rating and set a $66.00 target price (down from $69.00) on shares of Bristol-Myers Squibb in a report on Tuesday, January 31st. Vetr downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $58.05 target price for the company. in a report on Monday, February 27th. BMO Capital Markets downgraded shares of Bristol-Myers Squibb from a “market perform” rating to an “underperform” rating and set a $47.00 target price for the company. in a report on Wednesday, May 3rd. Argus restated a “buy” rating and set a $75.00 target price on shares of Bristol-Myers Squibb in a report on Wednesday, February 22nd. Finally, Robert W. Baird assumed coverage on shares of Bristol-Myers Squibb in a report on Tuesday, April 25th. They set an “outperform” rating for the company.

In other news, EVP Sandra Leung sold 92,405 shares of Bristol-Myers Squibb stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $57.02, for a total transaction of $5,268,933.10. Following the sale, the executive vice president now owns 488,063 shares in the company, valued at $27,829,352.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Theodore R. Samuels II acquired 12,000 shares of the company’s stock in a transaction dated Monday, February 27th. The shares were purchased at an average price of $56.77 per share, for a total transaction of $681,240.00. Following the purchase, the director now directly owns 12,000 shares of the company’s stock, valued at $681,240. The disclosure for this purchase can be found here. Insiders have sold 190,501 shares of company stock worth $10,690,203 in the last quarter. Insiders own 0.24% of the company’s stock.

Several hedge funds have recently bought and sold shares of the stock. Oppenheimer & Co. Inc. raised its stake in Bristol-Myers Squibb by 40.5% in the third quarter. Oppenheimer & Co. Inc. now owns 363,030 shares of the biopharmaceutical company’s stock worth $19,575,000 after buying an additional 104,669 shares in the last quarter. Union Bankshares Corp raised its stake in shares of Bristol-Myers Squibb by 12.2% in the first quarter. Union Bankshares Corp now owns 4,405 shares of the biopharmaceutical company’s stock worth $240,000 after buying an additional 480 shares during the period. Norges Bank bought a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth about $770,318,000. Stockman Asset Management raised its stake in shares of Bristol-Myers Squibb by 144.7% in the third quarter. Stockman Asset Management now owns 35,425 shares of the biopharmaceutical company’s stock worth $1,910,000 after buying an additional 20,950 shares during the period. Finally, Bayesian Capital Management LP raised its stake in shares of Bristol-Myers Squibb by 670.7% in the fourth quarter. Bayesian Capital Management LP now owns 29,286 shares of the biopharmaceutical company’s stock worth $1,711,000 after buying an additional 25,486 shares during the period. Institutional investors own 69.67% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Bristol-Myers Squibb Co (BMY) Receives Average Rating of “Hold” from Brokerages” was first published by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/05/26/bristol-myers-squibb-co-bmy-receives-average-rating-of-hold-from-brokerages.html.

Bristol-Myers Squibb (NYSE:BMY) traded down 0.77% during trading on Friday, reaching $53.97. 4,968,194 shares of the company were exchanged. Bristol-Myers Squibb has a 12 month low of $46.01 and a 12 month high of $77.12. The stock has a 50 day moving average price of $54.27 and a 200 day moving average price of $55.27. The firm has a market capitalization of $88.91 billion, a PE ratio of 18.75 and a beta of 1.00.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, April 27th. The biopharmaceutical company reported $0.84 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.72 by $0.12. Bristol-Myers Squibb had a net margin of 22.94% and a return on equity of 31.39%. The firm had revenue of $4.93 billion during the quarter, compared to the consensus estimate of $4.75 billion. During the same period last year, the firm posted $0.74 EPS. The firm’s revenue for the quarter was up 12.3% on a year-over-year basis. On average, analysts expect that Bristol-Myers Squibb will post $2.95 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Monday, May 1st. Stockholders of record on Friday, April 7th were paid a dividend of $0.39 per share. The ex-dividend date was Wednesday, April 5th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 2.89%. Bristol-Myers Squibb’s dividend payout ratio is currently 58.87%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

12 Month Chart for NYSE:BMY

Receive News & Ratings for Bristol-Myers Squibb Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co and related companies with MarketBeat.com's FREE daily email newsletter.